Biotech & Pharma
Health Tech
Politics
Health & Science
Team
Exclusive analysis of biotech, pharma, and the life sciences
Topics
Columns
Tools
Events
Team
Account
More
Follow Us
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
By Ed Silverman Dec. 2, 2021
Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day, given the clear and sunny skies — and delicious breezes — enveloping the Pharmalot campus this morning. This calls for celebration with a cup of stimulation, and we are opening a new package of maple bourbon for the occasion. Winter, after all, is nearly upon us. What is upon us right now, however, is our ever-growing to-do list. Sound familiar? So… here are some items of interest. Have a great day, everyone. …
AstraZeneca (AZN) is dropping plans to test its Covid-19 vaccine as a booster in the U.S., Bloomberg News writes, citing a letter sent to participants in the clinical trial that urged volunteers to seek a third dose elsewhere. After discussions with the U.S. government, it became clear that the drug maker was unlikely to pursue plans to assess a third dose of its vaccine, according to the letter sent by New York’s Montefiore Medical Center to trial participants. AstraZeneca was one of the first vaccine developers out of the gate, but has yet to win clearance to sell the shot in the U.S. after facing questions about its clinical trial results and side effects.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
Pharmalot Columnist, Senior Writer
Ed covers the pharmaceutical industry.
STAT+
This name will appear with your comment
There was an error saving your display name. Please check and try again.
By Ed Silverman
By Ed Silverman
advertisement
By Angus Chen
By
By Rachel Cohrs
Reporting from the frontiers of health and medicine
